Cydan Secures $10,000,000 New Funding

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    300 Technology Square 8th Floor Cambridge, MA 02139
  • Company Description
    Cydan is an orphan drug accelerator that identifies and de-risks compounds with therapeutic and commercial potential. Our rigorous process generates data to support a development path and new company formation.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Proceeds from this expanded round will be used to execute Cydan’s unique model of de-risking assets to support the launch of new companies focused on rare diseases.
  • M&A Terms
  • Venture Investor
    Lundbeckfond Ventures
  • Venture Investor
    Bay City Capital
  • Venture Investor
    New Enterprise Associates
  • Venture Investor
    Alexandria Venture Investments

Trending on Xconomy